SCHEMBL10143822

SCHEMBL10143822

Cc1nc2c(-c3ccc[nH]c3=O)c(C(=O)NS(C)(=O)=O)n(Cc3cc4ccccc4nc3Cl)c2cc1F

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C8 P10632 1/20 0.63
KMT2A Q03164 8/20 0.40
MEN1 O00255 2/20 0.35
RCE1 Q9Y256 1/20 0.35
KDM4E B2RXH2 3/20 0.33
ALDH1A1 P00352 3/20 0.33
FAAH O00519 1/20 0.32
CCR2 P41597 1/20 0.32
HDAC3 O15379 1/20 0.32
HDAC4 P56524 1/20 0.32
HDAC1 Q13547 1/20 0.32
HDAC7 Q8WUI4 1/20 0.32
HDAC2 Q92769 1/20 0.32
HDAC10 Q969S8 1/20 0.32
HDAC11 Q96DB2 1/20 0.32
HDAC8 Q9BY41 1/20 0.32
HDAC6 Q9UBN7 1/20 0.32
HDAC9 Q9UKV0 1/20 0.32
HDAC5 Q9UQL6 1/20 0.32
CYP1A2 P05177 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10142451 0.91 CYP2C8 (0.52) CYP2C8KMT2AMEN1KDM4EALDH1A1
SCHEMBL14802313 0.90 CYP2C8 (0.65) CYP2C8KMT2AMEN1RCE1KDM4E
SCHEMBL13926196 0.89 CYP2C8 (0.69) CYP2C8KMT2AMEN1RCE1KDM4E
SCHEMBL10143360 0.89 CYP2C8 (0.79) CYP2C8KMT2AMEN1RCE1KDM4E
SCHEMBL832847 0.86 CYP2C8 (0.65) CYP2C8KMT2AMEN1RCE1FAAH
SCHEMBL10143131 0.86 CYP2C8 (0.48) CYP2C8KMT2AMEN1RCE1KDM4E
SCHEMBL832432 0.85 CYP2C8 (0.69) CYP2C8KMT2AMEN1RCE1KDM4E
SCHEMBL832115 0.85 CYP2C8 (0.62) CYP2C8KMT2AMEN1RCE1KDM4E
SCHEMBL13126251 0.84 CYP2C8 (0.45) CYP2C8KMT2AMEN1RCE1KDM4E
SCHEMBL831987 0.84 CYP2C8 (0.60) CYP2C8KMT2AMEN1RCE1SCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8404845-B2 2,3-substituted azaindole derivatives for treating viral infections MERCK SHARP & DOHME CORP. (US) 2013-03-26 US disclosed
EP-2195317-B1 2,3-SUBSTITUTED AZAINDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS SCHERING CORP (US) 2012-01-18 EP disclosed
US-20100239527-A1 2,3-SUBSTITUTED AZAINDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS SCHERING CORPORATION (US) 2010-09-23 US disclosed
WO-2009032125-A1 2,3-SUBSTITUTED AZAINDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS SCHERING CORPORATION (US) 2009-03-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100239527-A1 2,3-SUBSTITUTED AZAINDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS HAVCR2, AZI2, ZC3HAV1 CYP2C8 649/4885KMT2A 164/4885MEN1 1639/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.